Buprenorphine for treating cancer pain

Area of Science:

• Oncology
• Pain Management
• Pharmacology

Background:

• Cancer pain frequently requires strong analgesics like buprenorphine, fentanyl, and morphine.
• Strong opioids are not universally effective or well-tolerated for all cancer pain patients.
• This review evaluates buprenorphine's efficacy and tolerability against other analgesic options for cancer pain.

Purpose of the Study:

• To assess the effectiveness of buprenorphine in managing cancer pain.
• To evaluate the tolerability of buprenorphine in adult and pediatric cancer patients.
• To compare buprenorphine with other analgesic treatments for cancer pain.

Main Methods:

• Conducted a systematic search of multiple databases (CENTRAL, MEDLINE, EMBASE, Web of Science, BIOSIS) and clinical trial registries up to January 2015.
• Included randomized controlled trials comparing buprenorphine (any formulation/route) with placebo or active drugs for cancer pain.
• Data were extracted independently by two reviewers; results were summarized narratively due to inability to meta-analyze, with evidence quality assessed using GRADE.

Main Results:

• Nineteen studies with 1421 patients were analyzed, comparing 16 different interventions.
• Buprenorphine showed superiority in five studies, no difference in three, and inferiority in three when compared to other drugs.
• Sublingual buprenorphine offered faster pain relief than subdermal, with similar efficacy and adverse events; intramuscular buprenorphine had higher adverse events than suppositories. Transdermal buprenorphine showed mixed results against placebo. Evidence quality was very low.

Conclusions:

• Buprenorphine's role in cancer pain management remains unclear, potentially as a fourth-line option for select patients.
• Sublingual and injectable buprenorphine routes demonstrated more defined analgesic effects.
• Transdermal buprenorphine studies raised more questions, and a variety of analgesics are crucial for heterogeneous palliative care patients.